TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Consistency of self-reported marijuana use with urine drug testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: risky alcohol consumption at the club
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: risk of alcohol-related harm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: possible alcohol dependence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HBV reactivation rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: HBsAg reverse seroconversion rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Endometrial hyperplasia or malignancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Symptom responses to therapy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of women recruited
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean Systolic Arterial Pressure (SAP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean Diastolic Arterial Pressure (DAP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pain measured on a 10-point visual analogue scale (VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complications during surgical procedures
Endpoint domain: Adverse events/effects
Primary endpoint: Signs or symptoms of maxillary sinus disease
Endpoint domain: Adverse events/effects
Primary endpoint: Bone percentages in biopsies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Range of motion loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Strength of plantar flexion recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to return to work and sports activities
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: body balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: abdominal activity in myocardial perfusion SPECT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MMEF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Systolic blood pressure response to angiotensin II
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Muscle mass increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Having an exercise partner
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Help with household duties
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Satisfaction with support
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: motion in all three planes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ease of removal
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Late complications (adhesions)
Endpoint domain: Adverse events/effects
Primary endpoint: Use of pain medication after surgery
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Tibial slope correction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Valgus alignment correction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: forearm arterial access site occlusion rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: episodes of phlebitis
Endpoint domain: Adverse events/effects
Primary endpoint: percentage reduction in area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients who achieved disease remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Costs for rituximab treatment and hospitalizations
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Severe adverse reaction at second rituximab dose
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of episodes with acceptable symptom relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to acceptable symptom relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PBS use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: average alcohol use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Parenting program initiation
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Parent attendance in sessions
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Leisure competence
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Favorable neurological outcome at discharge
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: rosuvastatin AUC(0‐t)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity and specificity of MRA for disease detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: mean milk volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intraocular pressure (IOP) of 23 mm Hg or more
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Chronic hypotony
Endpoint domain: Adverse events/effects
Primary endpoint: Time to distant progression
Endpoint domain: Mortality/survival
Primary endpoint: Efficacy of treatment (cured, markedly effective, effective, failed)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PDA (Partner Relationship Assessment)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Substance-related problems
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IPV (Intimate Partner Violence)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: β-cell function improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in attitudes (total scores)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Improvement in VF-14 score
Endpoint domain: Life impact
Endpoint subdomain: Visual functioning
Primary endpoint: Decline in trouble with vision
Endpoint domain: Life impact
Endpoint subdomain: Visual functioning
Primary endpoint: Improvement in satisfaction with vision
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: PCEF (Peak Cough Expiratory Flow)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: parasite recrudescence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Emergency department returns
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Clinical response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Remission (score below 150 on the Crohn's Disease Activity Index)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Adequate adherence to clinical appointments
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Discontinuation of treatment due to side effects
Endpoint domain: Adverse events/effects
Primary endpoint: knee abduction moments
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: ACTH-stimulated 21DF sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: mean GI reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean BOP reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cost of achieving an additional mother in the labour force
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Improvement of spasticity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neuromuscular outcomes
Primary endpoint: Discontinuation of brace use
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of fractures avoided
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incremental cost per quality-adjusted life-year gained
Endpoint domain: Resource use
Primary endpoint: Tibialis anterior muscle activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Attainment of reflection and critical reflection
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: OSCE scores for task completion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: OSCE scores for ultrasound image quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: self-assessed competence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage change in HS severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: morphine reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lipodystrophy incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction of radiation-induced cancer mortality risk
Endpoint domain: Mortality/survival
Primary endpoint: DNA double-strand break reductions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Terminal ileum intubation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Down-regulation of osteogenic gene expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Health risk indicators improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Seizure frequency change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Forearm resistance vessel responses to GTN
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Teacher stress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Irrational beliefs about teaching
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: mean PR interval increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Plasma ratio of n‐6 to n‐3 fatty acids
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total number of leukocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Total number of platelets
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Serum VEGF concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NHS prescription cost per patient
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Cost per successful treatment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Incidence of femoral DVT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Proximal seal zone coverage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Primary endpoint improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dinner energy intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Effectiveness of Chinese medicine on flat wart
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of H2O2 production
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in NO bioavailability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in myocardial cell survival
Endpoint domain: Mortality/survival
Primary endpoint: Pain at rest and at movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sedative events in the early post-operative period
Endpoint domain: Adverse events/effects
Primary endpoint: TIMI grade 3 flow after PCI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: in-stent thrombosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of hyperkalemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall satisfaction with anesthesia
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Pre-albumin and transferrin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Interleukin-6 and tumor necrosis factor-α levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Nutritional support costs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: treatment engagement rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in bone density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Quality of examination ratings
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Improvements in dyspnoea
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Amplitude of postural muscle activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: days to first moderate or severe exacerbation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 2-year relapse-free survival rates
Endpoint domain: Mortality/survival
Primary endpoint: acute toxicity (grade III or IV)
Endpoint domain: Adverse events/effects
Primary endpoint: early mortality (0-45 days)
Endpoint domain: Mortality/survival
Primary endpoint: Post-operative nausea and vomiting (PONV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average number of medications prescribed
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Estimated total monthly medication costs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Mortality and morbidity from cardiac, neurologic or cognitive complications
Endpoint domain: Mortality/survival
Primary endpoint: Deterioration in quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Response entropy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: State entropy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Quality of urograms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in serum triglycerides
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Increase in serum high-density lipoprotein cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Pain on walking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ninety day postoperative mortality
Endpoint domain: Mortality/survival
Primary endpoint: Decrement of FMD > 50%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of diarrhea events
Endpoint domain: Adverse events/effects
Primary endpoint: Severity of diarrhea (Grade 3 and 4)
Endpoint domain: Adverse events/effects
Primary endpoint: Chemotherapy discontinuation rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Physical subscale score of the CHQ-PF28
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Psychosocial subscale score of the CHQ-PF28
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Drug leakage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Predictive of cardiovascular events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: mRNA levels of alkaline phosphatase and other markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cardiovascular death, heart failure hospitalization, or aborted cardiac arrest
Endpoint domain: Mortality/survival
Primary endpoint: cellular Ag85A-specific mucosal and systemic immune responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: transient but significant respiratory adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: pseudoneurological complaints
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Short Form 36 physical component summary score improvement
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: PEP 1:2 ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean shear stiffness restored ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Mean torsional stiffness restored ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Cost-effectiveness of moisturizing cream treatment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: application, knowledge, and attitudes scale scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Regular progestogen-related bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hamilton Rating Scale for Depression (HRS-D) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recovery from depressive episode (HRS-D <=7)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in smoking rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Improvements in depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: C max (rate of IBU absorption)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCL (extent of IBU absorption)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: T max (time to reach C max)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximum postoperative creatine kinase isoenzyme MB levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: maximum postoperative troponin-T levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Global oxygen transport
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Regional hemodynamics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Recovery from sevoflurane anaesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in bispectral index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ADL decline during hospitalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Failure to recover ADL function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical remission at Week 11
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sinus membrane thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time curve (AUC)(0-24)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 6beta-hydroxycortisol/cortisol ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Number of lymph node metastasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: change in estimated glomerular filtration rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: change in urinary albumin excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: control of systolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Attendance rates
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Delivery at less than 37 weeks of gestation
Endpoint domain: Mortality/survival
Primary endpoint: Delivery at less than 35 weeks of gestation
Endpoint domain: Mortality/survival
Primary endpoint: Delivery at less than 32 weeks of gestation
Endpoint domain: Mortality/survival
Primary endpoint: Stress levels measured by SC peaks/sec
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CMV-specific CD8 T-cell counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: AVN incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Muscle soreness immediately after the marathon run
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Overall improvement of scars
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient-rated improvement in scars
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Independent reviewer-rated improvement in scars
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes